These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 1402902

  • 21. Glycosaminoglycan and proteoglycan inhibit the depolymerization of beta2-microglobulin amyloid fibrils in vitro.
    Yamaguchi I, Suda H, Tsuzuike N, Seto K, Seki M, Yamaguchi Y, Hasegawa K, Takahashi N, Yamamoto S, Gejyo F, Naiki H.
    Kidney Int; 2003 Sep; 64(3):1080-8. PubMed ID: 12911560
    [Abstract] [Full Text] [Related]

  • 22. Differential binding of vascular cell-derived proteoglycans (perlecan, biglycan, decorin, and versican) to the beta-amyloid protein of Alzheimer's disease.
    Snow AD, Kinsella MG, Parks E, Sekiguchi RT, Miller JD, Kimata K, Wight TN.
    Arch Biochem Biophys; 1995 Jun 20; 320(1):84-95. PubMed ID: 7793988
    [Abstract] [Full Text] [Related]

  • 23. Common binding sites for beta-amyloid fibrils and fibroblast growth factor-2 in heparan sulfate from human cerebral cortex.
    Lindahl B, Westling C, Giménez-Gallego G, Lindahl U, Salmivirta M.
    J Biol Chem; 1999 Oct 22; 274(43):30631-5. PubMed ID: 10521448
    [Abstract] [Full Text] [Related]

  • 24. Amyloid-beta interactions with chondroitin sulfate-derived monosaccharides and disaccharides. implications for drug development.
    Fraser PE, Darabie AA, McLaurin JA.
    J Biol Chem; 2001 Mar 02; 276(9):6412-9. PubMed ID: 11106653
    [Abstract] [Full Text] [Related]

  • 25. Binding of heparan sulfate glycosaminoglycan to beta-amyloid peptide: inhibition by potentially therapeutic polysulfated compounds.
    Leveugle B, Scanameo A, Ding W, Fillit H.
    Neuroreport; 1994 Jun 27; 5(11):1389-92. PubMed ID: 7522615
    [Abstract] [Full Text] [Related]

  • 26. Amyloid-like fibril formation by tachykinin neuropeptides and its relevance to amyloid β-protein aggregation and toxicity.
    Singh PK, Maji SK.
    Cell Biochem Biophys; 2012 Sep 27; 64(1):29-44. PubMed ID: 22628076
    [Abstract] [Full Text] [Related]

  • 27. The effects of sodium sulfate, glycosaminoglycans, and Congo red on the structure, stability, and amyloid formation of an immunoglobulin light-chain protein.
    McLaughlin RW, De Stigter JK, Sikkink LA, Baden EM, Ramirez-Alvarado M.
    Protein Sci; 2006 Jul 27; 15(7):1710-22. PubMed ID: 16751605
    [Abstract] [Full Text] [Related]

  • 28. Critical balance of electrostatic and hydrophobic interactions is required for beta 2-microglobulin amyloid fibril growth and stability.
    Raman B, Chatani E, Kihara M, Ban T, Sakai M, Hasegawa K, Naiki H, Rao ChM, Goto Y.
    Biochemistry; 2005 Feb 01; 44(4):1288-99. PubMed ID: 15667222
    [Abstract] [Full Text] [Related]

  • 29. Partially unfolded states of beta(2)-microglobulin and amyloid formation in vitro.
    McParland VJ, Kad NM, Kalverda AP, Brown A, Kirwin-Jones P, Hunter MG, Sunde M, Radford SE.
    Biochemistry; 2000 Aug 01; 39(30):8735-46. PubMed ID: 10913285
    [Abstract] [Full Text] [Related]

  • 30. Amyloid beta protein precursor is possibly a heparan sulfate proteoglycan core protein.
    Schubert D, Schroeder R, LaCorbiere M, Saitoh T, Cole G.
    Science; 1988 Jul 08; 241(4862):223-6. PubMed ID: 2968652
    [Abstract] [Full Text] [Related]

  • 31. Amyloid fibril toxicity in Alzheimer's disease and diabetes.
    Lorenzo A, Yankner BA.
    Ann N Y Acad Sci; 1996 Jan 17; 777():89-95. PubMed ID: 8624132
    [Abstract] [Full Text] [Related]

  • 32. Localization of human serum amyloid P component and heparan sulfate proteoglycan in in vitro-formed Abeta fibrils.
    Holm Nielsen E, Nybo M, Junker K, Toftedal Hansen P, Rasmussen IM, Svehag SE.
    Scand J Immunol; 2000 Aug 17; 52(2):110-2. PubMed ID: 10931376
    [Abstract] [Full Text] [Related]

  • 33. Sulfonated dyes attenuate the toxic effects of beta-amyloid in a structure-specific fashion.
    Pollack SJ, Sadler II, Hawtin SR, Tailor VJ, Shearman MS.
    Neurosci Lett; 1995 Sep 15; 197(3):211-4. PubMed ID: 8552301
    [Abstract] [Full Text] [Related]

  • 34. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red.
    Lorenzo A, Yankner BA.
    Proc Natl Acad Sci U S A; 1994 Dec 06; 91(25):12243-7. PubMed ID: 7991613
    [Abstract] [Full Text] [Related]

  • 35. Histidine residues underlie Congo red binding to A beta analogs.
    Inouye H, Nguyen JT, Fraser PE, Shinchuk LM, Packard AB, Kirschner DA.
    Amyloid; 2000 Sep 06; 7(3):179-88. PubMed ID: 11019858
    [Abstract] [Full Text] [Related]

  • 36. Glycosaminoglycans enhance the fibrillation propensity of the β2-microglobulin cleavage variant--ΔK58-β2m.
    Corlin DB, Johnsen CK, Nissen MH, Heegaard NH.
    Biochem Biophys Res Commun; 2010 Nov 12; 402(2):247-51. PubMed ID: 20939999
    [Abstract] [Full Text] [Related]

  • 37. Effect of amino-acid substitutions on Alzheimer's amyloid-beta peptide-glycosaminoglycan interactions.
    McLaurin J, Fraser PE.
    Eur J Biochem; 2000 Nov 12; 267(21):6353-61. PubMed ID: 11029577
    [Abstract] [Full Text] [Related]

  • 38. Amyloid from a histochemical perspective. A review of the structure, properties and types of amyloid, and a proposed staining mechanism for Congo red staining.
    Dapson RW.
    Biotech Histochem; 2018 Nov 12; 93(8):543-556. PubMed ID: 30403893
    [Abstract] [Full Text] [Related]

  • 39. A high resolution ultrastructural study of experimental murine AA amyloid.
    Inoue S, Kisilevsky R.
    Lab Invest; 1996 Mar 12; 74(3):670-83. PubMed ID: 8600318
    [Abstract] [Full Text] [Related]

  • 40. Amyloid fibril formation by a synthetic peptide from a region of human acetylcholinesterase that is homologous to the Alzheimer's amyloid-beta peptide.
    Cottingham MG, Hollinshead MS, Vaux DJ.
    Biochemistry; 2002 Nov 19; 41(46):13539-47. PubMed ID: 12427014
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.